www.abbvie.com Open in urlscan Pro
52.49.237.22  Public Scan

Form analysis
2 forms found in the DOM

GET /search.html

<form method="get" class="cmp-searchinputfield__form" action="/search.html">
  <div class="cmp-searchinputfield__form-group">
    <div>
      <input autocomplete="off" type="search" size="10" class="cmp-searchinputfield__input" name="search" title="search" spellcheck="false" placeholder="Type in your search and press enter..." tabindex="0"
        data-mobile-placeholder="Type in your search..." data-desktop-placeholder="Type in your search and press enter..." aria-hidden="false"> <input type="hidden" name="_charset_" value="UTF-8">
    </div>
  </div>
</form>

GET /search.html

<form class="cmp-searchinputfield__mobile-form" method="get" action="/search.html">
  <div class="cmp-searchinputfield__mobile-form-group">
    <div>
      <input aria-label="Search" class="cmp-searchinputfield__mobile-input" autocomplete="off" type="search" size="10" name="search" title="search" spellcheck="false" tabindex="0" placeholder="Type in your search..."
        data-mobile-placeholder="Type in your search..." data-desktop-placeholder="Type in your search and press enter..." aria-hidden="false"> <input type="hidden" name="_charset_" value="UTF-8">
    </div>
  </div>
</form>

Text Content

Skip to main content
Global • EN


AFRICA

Algeria

South Africa and Sub-Saharan Africa

Tunisia


ASIA PACIFIC

Australia

China

Hong Kong

Japan

Korea

Malaysia

New Zealand

Singapore

Taiwan


EUROPE

Austria

Belgium FR | NL

Bosnia & Herzegovina

Bulgaria

Croatia

Czech Republic

Denmark

Finland

France

Germany

Greece

Hungary

Ireland

Italy

Netherlands

Norway

Poland

Portugal

Romania

Russia

Serbia

Slovakia

Slovenia

Spain

Sweden

Switzerland DE |  FR

Turkey

Ukraine

United Kingdom


LATIN AMERICA / CARIBBEAN

Mexico

Puerto Rico


MIDDLE EAST

Israel

Lebanon

Saudi Arabia

UAE


NORTH AMERICA

Canada EN | FR

United States


SOUTH AMERICA

Argentina

Brazil

Chile

Colombia

Uruguay

 * Investors
 * News Center
 * Patient Assistance


Menu
 * Our Company
   * Explore Our Company
   * Our Principles
   * Equity, Equality, Diversity & Inclusion
     * Explore Equity, Equality, Diversity & Inclusion
     * AbbVie's commitment to racial justice
     * Impact Through Inclusion
   * Key Facts
   * Our Leaders
   * Positions & Views
   * Ethics & Compliance
     * Explore Ethics & Compliance
     * Ethics & Compliance Program
     * AbbVie Code of Business Conduct
     * Physician & Other Payments
   * Policies & Disclosures
     * Explore Policies & Disclosures
     * Protecting Data
   * Our History
   * All Stories
 * Our Science
   * Explore Our Science
   * Therapeutic Focus Areas
     * Explore Therapeutic Focus Areas
     * Immunology
     * Oncology
     * Neuroscience
     * Virology
     * Eye Care
   * Technologies & Platforms
   * Pipeline
     * Explore Pipeline
     * Devices
   * Clinical Trials
     * Explore Clinical Trials
     * Conduct of Clinical Trials & Postmarketing Commitments
     * Clinical Trials Data & Information Sharing
   * Products
   * Our R&D Leaders
   * COVID-19 R&D
   * Publications
   * Our Science Stories
 * Societal Impact
   * Explore Societal Impact
   * For the Well-Being of Our Patients
     * Explore For the Well-Being of Our Patients
     * Innovating for Patients
     * Upholding the Highest Quality
     * Patient Health & Engagement
     * Independent Healthcare Grants
   * For the Growth of Our Employees
     * Explore For the Growth of Our Employees
     * Cultivating a Diverse & Inclusive Workplace
     * Developing Our People’s Capabilities
     * Protecting Human Rights & Workplace Safety
     * Providing Resources & Support for Employee Well-Being
   * For the Strength of Our Communities
     * Explore For the Strength of Our Communities
     * Supporting Long-Term Community Strength
     * Advancing Environmental Sustainability
     * Serving Communities Through Philanthropy
   * For the Resilience of Our Business
     * Explore For the Resilience of Our Business
     * Delivering Sustainable Growth
     * Operating with Accountability
     * Key Performance Indicators
 * Careers
   * Explore Careers
   * Search All Jobs
   * Benefits
   * Development Programs
     * Explore Development Programs
     * Employee Development Programs
   * Employee Resource Groups
     * Explore Employee Resource Groups
     * AbbVie Pride
     * Ability at AbbVie
     * AHORA Hispanic/Latino
     * Asian Leadership Network
     * Black Business Network
     * Women Leaders in Action
     * Veterans
   * Roles
     * Explore Roles
     * Corporate
     * Research & Development
     * Operations
     * Commercial
     * Business Technology Solutions
     * U.S. Student Opportunities
     * U.S. Professional Programs
   * AbbVie Around the World
   * Our People Stories
 * Partnerships
   * Explore Partnerships
   * Our Approach
   * Areas of interest
   * Partnering Days
   * AbbVie Ventures
     * Explore AbbVie Ventures
     * Team
     * Portfolio
   * Additional Collaboration Opportunities
     * Explore Additional Collaboration Opportunities
     * Investigator-Initiated Studies (IIS)
     * Contract Manufacturing

 * Investors
 * News Center
 * Patient Assistance

Search

Close Search
Type in your search...
Toggle Ancillary Navigation



FROM ONE MILLION GENOMES TO INSIGHT

Experts from our Genomics Research Center aim to use DNA data to discover and
develop medicines faster.































































See the story
Pause Play
 1. 
 2. 
 3. 

April 19, 2022 / Press releases

Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at
the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual
Meeting

April 14, 2022 / Press releases

AbbVie to Host First-Quarter 2022 Earnings Conference Call

April 13, 2022 / Press releases

AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20)
from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma
(LBCL)
Feature


ABBVIE'S RESPONSE TO THE UKRAINE CRISIS


Feature


ABBVIE'S RESPONSE TO COVID-19


Patients


ABBVIE’S PATIENT ASSISTANCE




OUR APPROACH TO INNOVATION BUILDS ON STRONG SCIENCE COMBINED WITH THE DRIVE TO
FIND SOLUTIONS WHERE THE NEED IS THE GREATEST

Our science


PIPELINE

Advancing medicines with strong clinical performance in areas of great need




FOCUS AREAS

Driving innovation across oncology, immunology, neuroscience and more




CAREERS

Work with us to turn world-class research into life-changing results




OUR COMMITMENT TO SCIENCE IS A COMMITMENT TO BETTER OUR SOCIETY

Societal Impact


$35 MILLION

donated to support COVID-19 relief efforts across the globe




26 NONPROFITS

received support from the AbbVie COVID-19 Community Resilience Fund for hard-hit
communities around the world






88%

of waste diverted from landfills in 2019. Our goal is to achieve zero waste to
landfill by 2035.




1 of 3
2 of 3
3 of 3
Previous Next
Pause Play
 1. slide1
 2. slide2
 3. slide3


BY PUTTING PATIENTS FIRST, WE EXPLORE NEW MEDICAL INNOVATIONS AND WAYS TO
ENHANCE ACCESS

Patients

If we bring a new medicine to market, it can help patients worldwide, as opposed
to the 20 or so patients we might see in clinic in one day. That's what drives
me. It's the greater impact we can have by working here at AbbVie.

Kyle Holen, M.D., Vice President, General Medicine and Infectious Diseases




ABBVIE COMBINES ADVANCED SCIENCE, EXPERTISE AND PASSION TO SOLVE THE WORLD’S
MOST SERIOUS HEALTH ISSUES AND HAVE A REMARKABLE IMPACT ON PEOPLE’S LIVES

Our company


2019 DOW JONES SUSTAINABILITY WORLD INDEX

AbbVie was named to the DJSI World Index for the seventh year in a row for our
responsible economic, environmental and social performance










DIVERSITYINC TOP 50 COMPANIES FOR PHILANTHROPY

AbbVie ranked No. 5 on DiversityInc’s list for 2020. DiversityInc also
recognized AbbVie as one of the Top 50 Companies for Diversity this year


































































SEVEN YEARS ON THE CIVIC 50

For the seventh year in a row, AbbVie was named on The Civic 50, a listing of
the most community-minded companies in the United States


1 of 3
2 of 3
3 of 3
Previous Next
Pause Play
 1. slide1
 2. slide3
 3. slide3


Return to top
 * Stories
 * Patients
 * Suppliers
 * Contact

 1. Follow us on Facebook opens in a new window
 2. Follow us on Twitter opens in a new window
 3. Follow us on LinkedIn opens in a new window
 4. Follow us on Instagram Follow us on Instagram opens in a new window
 5. Follow us on YouTube opens in a new window

 * Medical Information opens in a new window
 * Site Map
 * Privacy Policy
 * Terms of Use

Cookies Settings

Copyright © 2022 AbbVie Inc. North Chicago, Illinois, U.S.A.

Unless otherwise specified, all product names appearing in this internet site
are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or
affiliates. No use of any AbbVie trademark, trade name, or trade dress in this
site may be made without the prior written authorization of AbbVie Inc., except
to identify the product or services of the company.


×


YOU ARE ABOUT TO LEAVE THE ABBVIE WEBSITE

The product-specific site Internet site that you have requested is intended for
the residents of a particular country or countries, as noted on that site. As a
result, the site may contain information on pharmaceuticals that are not
approved in other countries or region. If you are a resident of a country other
than those to which the site is directed, please return to AbbVie.com or contact
your local AbbVie affiliate to obtain the appropriate product information for
your country of residence. The Internet site that you have requested may not be
optimized to your screen size. Do you wish to continue to this product-specific
site?


YES



I agree


NO



I disagree
×


YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

The link below will take you out of the AbbVie family of websites. Links which
take you out of the AbbVie worldwide websites are not under the control of
AbbVie, and AbbVie is not responsible for the contents of any such site or any
further links from such site. AbbVie is providing these links to you only as a
convenience and the inclusion of any link does not imply endorsement of the
linked site by AbbVie. The Internet site that you have requested may not be
optimized to your screen size. Do you wish to leave this site?


YES



Accept


NO



Learn More


DISCLAIMER NOTICE - IMPORTANT

Recommended Offer for Allergan plc (“Allergan”) by AbbVie Inc. (“AbbVie”) (the
“Acquisition”) by means of a scheme of arrangement under Irish law (the
“Scheme”). You are attempting to enter the section of this website that is
designated for the publication of documents and information in connection with
the offer by AbbVie for Allergan announced on June 25, 2019 (the “Offer”).
ACCESS TO THIS SECTION OF THE WEBSITE MAY BE RESTRICTED UNDER SECURITIES LAWS IN
CERTAIN JURISDICTIONS. THIS NOTICE REQUIRES YOU TO CONFIRM CERTAIN MATTERS
(INCLUDING THAT YOU ARE NOT RESIDENT IN SUCH A JURISDICTION), BEFORE YOU MAY
OBTAIN ACCESS TO THE INFORMATION. THE INFORMATION IS NOT DIRECTED AT, AND IS NOT
INTENDED TO BE ACCESSIBLE BY, PERSONS RESIDENT IN ANY JURISDICTION WHERE TO DO
SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION. IF
YOU ARE NOT PERMITTED TO VIEW THE INFORMATION, OR VIEWING THE INFORMATION WOULD
RESULT IN A BREACH OF THE ABOVE, OR YOU ARE IN ANY DOUBT AS TO WHETHER YOU ARE
PERMITTED TO VIEW THE INFORMATION, PLEASE EXIT THIS WEBPAGE. THIS SECTION OF THE
WEBSITE CONTAINS ANNOUNCEMENTS, DOCUMENTS AND INFORMATION (TOGETHER THE
"INFORMATION") RELATING TO THE OFFER IN COMPLIANCE WITH THE IRISH TAKEOVER PANEL
ACT, 1997, TAKEOVER RULES 2013 (THE "IRISH TAKEOVER RULES"). THE INFORMATION IS
BEING MADE AVAILABLE IN GOOD FAITH AND FOR INFORMATION PURPOSES ONLY, AND ITS
AVAILABILITY IS SUBJECT TO THE TERMS AND CONDITIONS SET OUT BELOW. THE
INFORMATION IS NOT INTENDED TO, AND DOES NOT, CONSTITUTE OR FORM ANY PART OF AN
OFFER TO SELL OR OTHERWISE DISPOSE OF OR AN INVITATION OR THE SOLICITATION OF AN
OFFER TO PURCHASE OR OTHERWISE ACQUIRE ANY SECURITIES, OR THE SOLICITATION OF A
VOTE OR APPROVAL PURSUANT TO THE INFORMATION OR OTHERWISE. ANY PERSON SEEKING
ACCESS TO THIS SECTION OF ABBVIE’S WEBSITE REPRESENTS AND WARRANTS TO ABBVIE
THAT THEY ARE DOING SO FOR INFORMATION PURPOSES ONLY. BASIS OF ACCESS TO
INFORMATION Please read this notice carefully before clicking "I agree" or "I
disagree" below. This notice applies to all persons who view this section of the
website and, depending on where you live, it may affect your rights. This notice
may be amended or updated by AbbVie from time to time and it should be read
carefully in full each time you wish to view the website. In addition, the
content of the website, and its accessibility by certain persons, may be amended
at any time in whole or in part at the sole discretion of AbbVie. The
Information speaks only at the date of the relevant document or announcement and
AbbVie has, and accepts, no responsibility or duty to update any Information
(other than to the extent such duty arises as a matter of law or regulation).

Accept and continue

I agree

Return to AbbVie.com Home

I disagree